相关实验视频

Updated: Sep 12, 2025

Roux-en-Y Gastric Bypass Operation in Rats

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

手术前的葡萄糖类-1受体激动剂和腹手术结果:系统性审查

Ali Esparham¹, Erfan Sheikhbahaei², Hengameh Anari Moghadam¹

¹Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran.

Obesity surgery

|August 9, 2025

概括

手术前使用类似葡萄糖-1受体激动剂 (GLP-1RA) 有助于在代谢和腹手术 (MBS) 之前减肥,但可能会增加恶心,而不会影响重大并发症. 需要进一步的研究.

科学领域:

内分泌学在内分泌学.
胃肠病学胃肠病学
手术科学手术科学

背景情况:

代谢和减肥手术 (MBS) 是对肥胖的关键治疗方法.
在MBS之前优化患者健康对于成功的结果至关重要.
葡萄糖类-1受体激动剂 (GLP-1RA) 越来越多地用于体重管理.

研究的目的:

系统地审查在接受代谢和腹部手术 (MBS) 的患者手术前使用GLP-1受体激活剂 (GLP-1RA) 的证据.
评估手术前GLP-1RA使用对MBS结果的影响,包括减肥,并发症和糖尿病管理.

主要方法:

在Web of Science,Embase,PubMed和Scopus上进行系统的文献搜索.
包括观察性研究评估了手术前GLP-1RA使用对MBS结果的影响.
综合了11项已识别的观察性研究的结果.

主要成果:

手术前GLP-1RA与增加体重减轻和早期患者对MBS的优化有关.
观察到手术后恶心率增加,但主要并发症或再入院没有显著差异.
改善了糖尿病的结果,尽管术后减肥结果不一致,一些研究报告了更高的手术粘附率.

结论:

术前GLP-1RA可以促进减肥,优化患者的MBS,对糖尿病管理有好处.
虽然在重大并发症方面通常是安全的,但恶心增加是潜在的副作用.
需要进一步提供高质量的证据,以制定将GLP-1RA纳入手术前MBS协议的最终指导方针.

关键词:

腹症腹症是指腹症.复杂性复杂性复杂性葡萄糖类-1受体激动剂.利拉格卢提德 (Liraglutide) 是一种类药物.致病性肥胖症是一种病态的肥胖症.在手术前进行手术.塞马格卢提德 (semaglutide) 是一种类型的

更多相关视频

Sleeve Gastrectomy in Mice using Surgical Clips

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers

Published on: August 21, 2021

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...